IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced that it is presenting six in-person posters highlighting data from its phase 1 clinical trials investigating the company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”). The event is taking place July 16-20, 2023, in Amsterdam, Netherlands. “We are honored to have six posters accepted for presentation at AAIC 2023, a prestigious meeting of leading Alzheimer’s disease experts and pharmaceutical innovators,” said Ram Mukunda, CEO of IGC. “The data being presented at AAIC from our phase 1 clinical trial of IGC-AD1 demonstrates the positive impact of our patented cannabinoid formulation on neuropsychiatric symptoms such as agitation, apathy and the associated caregiver distress, without causing suicidal ideation or increasing blood pressure variability. Additionally, we are pleased to announce the presentation of our genotyping study analyzing the pharmacokinetics of THC metabolization in diverse patient groups. IGC is committed to increasing diversity in clinical trials and subsequently developing effective treatments for all who are impacted by Alzheimer’s disease. We are encouraged by the results of IGC-AD1 so far and we continue to drive progress in our phase 2 trial.”
To view the full press release, visit https://ibn.fm/pPapK
About IGC Pharma Inc.
IGC Pharma develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps (“dysmenorrhea”), premenstrual syndrome (“PMS”), and chronic pain. IGC has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”) based formulation that is currently in a 146-person phase 2 clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). IGC Pharma also markets a wellness brand, Holief(TM), that targets women experiencing premenstrual syndrome and menstrual cramps.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
